Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.77 |
| ▸ | PDE6C | P51160 | 3/20 | 0.77 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.69 |
| ▸ | PDE1A | P54750 | 2/20 | 0.69 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.69 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.69 |
| ▸ | PDE2A | O00408 | 1/20 | 0.69 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.69 |
| ▸ | PDE6D | O43924 | 1/20 | 0.69 |
| ▸ | PDE8A | O60658 | 1/20 | 0.69 |
| ▸ | PDE9A | O76083 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | PDE6A | P16499 | 1/20 | 0.69 |
| ▸ | PDE6G | P18545 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145682 | 1.00 | PDE5A (0.77) | PDE5APDE6CPDE3BPDE3APDE1A | |
| SCHEMBL25013643 | 0.94 | PDE5A (0.75) | PDE5APDE6CPDE3BPDE3APDE1A | |
| SCHEMBL31174347 | 0.94 | PDE5A (0.75) | PDE5APDE6CPDE3BPDE3APDE1A | |
| SCHEMBL28416630 | 0.93 | PDE5A (0.76) | PDE5APDE6CPDE3BPDE3APDE1A | |
| SCHEMBL28476705 | 0.92 | PDE5A (0.72) | PDE5APDE6CPDE3BPDE3APDE1A | |
| SCHEMBL30199753 | 0.89 | PDE5A (0.85) | PDE5APDE6CPDE3BPDE3APDE1A | |
| SCHEMBL25013469 | 0.89 | PDE5A (0.85) | PDE5APDE6CPDE3BPDE3APDE1A | |
| SCHEMBL7960838 | 0.87 | PDE5A (0.86) | PDE5APDE6CPDE1APDE1BPDE1C | |
| SCHEMBL7961020 | 0.87 | PDE5A (1.00) | PDE5APDE6CPDE1APDE1BPDE1C | |
| SCHEMBL18714952 | 0.86 | PDE5A (0.85) | PDE5APDE6CPDE3BPDE3APDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | disclosed |
| US-11833141-B2 | Topical formulations and compositions | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-12-05 | — | — | US | disclosed |
| WO-2023144614-A1 | NASAL COMPOSITIONS AND METHODS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-08-03 | — | — | WO | disclosed |
| US-20230020927-A1 | TOPICAL FORMULATIONS AND COMPOSITIONS | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-01-19 | — | — | US | disclosed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022175829-A1 | TOPICAL FORMULATIONS AND COMPOSITIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | disclosed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | disclosed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE5A 418/4885PDE6C 990/4885PDE3B 837/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE5A 418/4885PDE6C 990/4885PDE3B 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.